Spots Global Cancer Trial Database for guadecitabine
Every month we try and update this database with for guadecitabine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes | NCT02131597 | High Risk Myelo... | Guadecitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | NCT03308396 | Advanced Kidney... Kidney Cancer Clear Cell Rena... | Guadecitabine Durvalumab | 18 Years - | Big Ten Cancer Research Consortium | |
| Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT02901899 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Guadecitabine Laboratory Biom... Pembrolizumab | 18 Years - | Northwestern University | |
| Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | NCT02998567 | Castration-Resi... Non Small Cell ... | Guadecitabine Pembrolizumab ASTX727 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | NCT03576963 | Colorectal Aden... CpG Island Meth... Metastatic Micr... Refractory Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... | Guadecitabine Nivolumab | 18 Years - | University of Southern California | |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | NCT03179943 | Urothelial Carc... | Atezolizumab Guadecitabine | 18 Years - | Fox Chase Cancer Center | |
| Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | NCT02935361 | Chronic Myelomo... Myelodysplastic... Recurrent Acute... | Atezolizumab Guadecitabine | 18 Years - | University of Southern California | |
| Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | NCT02920008 | Acute Myeloid L... | guadecitabine Treatment Choic... | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | NCT02907359 | Myelodysplastic... Leukemia, Myelo... | Guadecitabine Treatment Choic... | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. | NCT03220477 | Lung Cancer | Pembrolizumab Guadecitabine Mocetinostat | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | NCT04340843 | Locally Advance... Metastatic Prim... Unresectable Pr... | Belinostat Biopsy Biospecimen Col... Computed Tomogr... Decitabine and ... Guadecitabine Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | NCT02684162 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Myelo... | Donor Lymphocyt... Guadecitabine Laboratory Biom... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | NCT03257761 | Extrahepatic Bi... Gallbladder Ade... Metastatic Panc... Recurrent Chola... Recurrent Gallb... Recurrent Hepat... Recurrent Intra... Recurrent Pancr... Stage III Gallb... Stage III Hepat... Stage III Intra... Stage III Pancr... Stage IIIA Gall... Stage IIIA Hepa... Stage IIIB Gall... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Gallbl... Stage IV Hepato... Stage IV Pancre... Stage IVA Gallb... Stage IVA Hepat... Stage IVA Intra... Stage IVB Gallb... Stage IVB Hepat... Stage IVB Intra... Unresectable Ga... Unresectable Pa... | Durvalumab Guadecitabine | 18 Years - | University of Southern California | |
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | NCT03308396 | Advanced Kidney... Kidney Cancer Clear Cell Rena... | Guadecitabine Durvalumab | 18 Years - | Big Ten Cancer Research Consortium | |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | NCT02684162 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Myelo... | Donor Lymphocyt... Guadecitabine Laboratory Biom... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | NCT04250246 | Melanoma Non Small Cell ... | Ipilimumab plus... Ipilimumab plus... | 18 Years - | Italian Network for Tumor Biotherapy Foundation | |
| Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | NCT03576963 | Colorectal Aden... CpG Island Meth... Metastatic Micr... Refractory Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... | Guadecitabine Nivolumab | 18 Years - | University of Southern California | |
| Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors | NCT02429466 | Germ Cell Tumor Testis Cancer Testicular Canc... | Guadecitabine (... | 18 Years - | Indiana University | |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | NCT04340843 | Locally Advance... Metastatic Prim... Unresectable Pr... | Belinostat Biopsy Biospecimen Col... Computed Tomogr... Decitabine and ... Guadecitabine Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT02096055 | Untreated Adult... | Cladribine Guadecitabine Idarubicin | 70 Years - | M.D. Anderson Cancer Center | |
| Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | NCT02998567 | Castration-Resi... Non Small Cell ... | Guadecitabine Pembrolizumab ASTX727 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | NCT02935361 | Chronic Myelomo... Myelodysplastic... Recurrent Acute... | Atezolizumab Guadecitabine | 18 Years - | University of Southern California | |
| Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | NCT02998567 | Castration-Resi... Non Small Cell ... | Guadecitabine Pembrolizumab ASTX727 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT02901899 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Guadecitabine Laboratory Biom... Pembrolizumab | 18 Years - | Northwestern University | |
| Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT02096055 | Untreated Adult... | Cladribine Guadecitabine Idarubicin | 70 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
